

# RESEARCH MODEL SEMINAR

## Subjects:

### Genetic Drift - What It Is and How to Minimize Its Impact on Your Research

The phenotypes of genetically modified mouse strains depend on the genetic mutation and background.

Genetic background is subject to genetic drift that may result in phenotypic drift over time.

You will learn about the following topics:

- The basis for genetic drift
- Case studies demonstrating genetic drift and its effects on experimental results
- The Jackson Laboratory's unique Genetic Stability Program to stop cumulative genetic drift

Steps to ensure the long-term genetic and phenotypic stability of your mutant mice.

### Key Differences among B6 Substrains and the Research Impact

The C57BL/6 inbred mouse (B6) is the most commonly used research strain.

This strain is the most well characterized the first to have its entire genome sequenced, and the genetic background strain of choice for most targeted mutations and transgenics.

The universal acceptance and demand for B6 mice has necessitated their production from multiple sources, introducing genetic and phenotypic variability that has important consequences for accurately interpreting and repeating research results.

We will discuss the following topics:

- A brief historical perspective on the development of B6 inbred mice and different substrains
- Recent publications highlighting significant physiological and behavioral differences among different B6 inbred mice
- The significance for control selection and experimental design

Key tips for avoiding common B6 research mistakes.

## Speaker:

### Kristin Lamont, PhD Technical Information Scientist

*Earned a BA in Biochemistry from Colgate University in 2003 and a PhD in Biomedical Sciences in 2009 from the Mayo Graduate School in Rochester, Minnesota. Her doctoral thesis focused on the regulation of the apoptosis inhibitor c-FLIP by androgens and anti-androgens in prostate cancer.*

*Joined the Jackson Laboratory in 2011 for a post-doctoral fellowship to develop a novel therapeutic strategy to target B-cell malignancies such as chronic lymphocytic leukemia. Kristin has over a decade of experience in tumor cell biology, cell signaling, and in vivo models of cancer.*

**When:** Friday 1 December from 10:30 - 13:30. Registration starts at 10:00.

**Where:** University of Bergen, BUS1, Barne- og Ungdomssjukehuset, Haukelandsbakken 15, Bergen.

**Price:** Free-of-charge.

**REGISTER NOW!** <https://da.surveymonkey.com/r/CNF9C78>

**Closing date for registration:** Wednesday 22 November 2017.

Join in on our discussions with specialists. We look forward to seeing you!

Best regards,

**Trude Sæterøy**

SCANBUR

*Sales Manager | Research Models Norway*

Mob. +47 9079 5780

[ts@scanbur.com](mailto:ts@scanbur.com)

**Tine Larsen**

SCANBUR

*Sales Manager | Research Models Sweden*

Mob. +45 3095 2114

[til@scanbur.com](mailto:til@scanbur.com)

**Karen Ekkelund Petersen**

SCANBUR

*PhD | DVM | Scientific Affairs Manager*

Mob. +45 3095 8910

[kep@scanbur.com](mailto:kep@scanbur.com)

